Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abacavir Sulfate

FDA-approved product (tablet, oral), marketed as Abacavir Sulfate, Ziagen.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Abacavir Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Immunodeficiency disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abacavir Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abacavir Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject

    NCT02159599 · start 2014-07

    Registered record
    Registry ID
    NCT02159599
    Conditions
    HIV Infection
    Interventions
    Darunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2016-04
    Enrolment
    249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionDarunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    PhasePhase 4
    Registry statusCompleted

  • A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

    NCT02105987 · start 2014-04

    Registered record
    Registry ID
    NCT02105987
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    ABC/DTG/3TC FDC; Ongoing cART regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-04
    Completion
    2015-12
    Enrolment
    555

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionABC/DTG/3TC FDC; Ongoing cART regimen
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers

    NCT02101216 · start 2014-03

    Registered record
    Registry ID
    NCT02101216
    Conditions
    Psoriasis
    Interventions
    Prurisol; Ziagen
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-03
    Completion
    2014-10
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionPrurisol; Ziagen
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

    NCT01440569 · start 2011-09

    Registered record
    Registry ID
    NCT01440569
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    COBI; DRV; NRTIs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2015-10
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionCOBI; DRV; NRTIs
    PhasePhase 3
    Registry statusCompleted

  • Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

    NCT01366547 · start 2011-06

    Registered record
    Registry ID
    NCT01366547
    Conditions
    Healthy Subjects; Infection, Human Immunodeficiency Virus
    Interventions
    Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg; Dolutegravir 50 mg; abacavir 600 mg/lamivudine 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-06
    Completion
    2011-07
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects; Infection, Human Immunodeficiency Virus
    InterventionDolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg; Dolutegravir 50 mg; abacavir 600 mg/lamivudine 300 mg
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

    NCT00799864 · start 2011-01

    Registered record
    Registry ID
    NCT00799864
    Conditions
    HIV-1
    Interventions
    Rilpivirine; Zidovudine; Abacavir; Tenofovir disoproxil fumarate; Lamivudine; Emtricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-01
    Completion
    2022-08
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionRilpivirine; Zidovudine; Abacavir; Tenofovir disoproxil fumarate +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

    NCT01227824 · start 2010-10-19

    Registered record
    Registry ID
    NCT01227824
    Conditions
    Infection, Human Immunodeficiency Virus I
    Interventions
    GSK1349572 (dolutegravir); raltegravir; GSK1349572 Placebo; ABC/3TC; TDF/FTC; raltegravir Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-10-19
    Completion
    2016-12-27
    Enrolment
    828

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus I
    InterventionGSK1349572 (dolutegravir); raltegravir; GSK1349572 Placebo; ABC/3TC +2 more
    PhasePhase 3
    Registry statusCompleted

  • Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients

    NCT01059422 · start 2010-10

    Registered record
    Registry ID
    NCT01059422
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Raltegravir; Abacavir/Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-10
    Completion
    2013-05
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionRaltegravir; Abacavir/Lamivudine
    PhasePhase 4
    Registry statusCompleted

  • Artery Elasticity After Switch From Epzicom to Truvada

    NCT00998582 · start 2009-10

    Registered record
    Registry ID
    NCT00998582
    Conditions
    HIV Infections
    Interventions
    Tenofovir disoproxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2009-10
    Completion
    2011-12
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTenofovir disoproxil
    PhasePhase 4
    Registry statusTerminated

  • HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

    NCT00978068 · start 2009-09

    Registered record
    Registry ID
    NCT00978068
    Conditions
    Malaria; HIV Infections
    Interventions
    Lopinavir/Ritonavir (LPV/r); Nevirapine (NVP); Efavirenz (EFV); 2 nucleoside reverse transcriptase inhibitor (NRTI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-01
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; HIV Infections
    InterventionLopinavir/Ritonavir (LPV/r); Nevirapine (NVP); Efavirenz (EFV); 2 nucleoside reverse transcriptase inhibitor (NRTI)
    PhasePhase 3
    Registry statusCompleted

  • Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

    NCT00708162 · start 2008-07

    Registered record
    Registry ID
    NCT00708162
    Conditions
    HIV Infection
    Interventions
    Elvitegravir; Raltegravir; EVG placebo; RAL placebo; Background regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2015-04
    Enrolment
    724

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionElvitegravir; Raltegravir; EVG placebo; RAL placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients

    NCT00647244 · start 2008-06

    Registered record
    Registry ID
    NCT00647244
    Conditions
    HIV Infections
    Interventions
    Tenofovir disoproxil fumarate; Abacavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-06
    Completion
    2010-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTenofovir disoproxil fumarate; Abacavir
    PhasePhase 4
    Registry statusCompleted

  • KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects

    NCT00549198 · start 2007-06

    Registered record
    Registry ID
    NCT00549198
    Conditions
    Infection, Human Immunodeficiency Virus I; HIV Infection
    Interventions
    Abacavir/lamivudine and efavirenz; Tenofovir/Emtricitabine and efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-06
    Completion
    2009-12
    Enrolment
    392

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus I; HIV Infection
    InterventionAbacavir/lamivudine and efavirenz; Tenofovir/Emtricitabine and efavirenz
    PhasePhase 4
    Registry statusCompleted

  • Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

    NCT00440947 · start 2007-03

    Registered record
    Registry ID
    NCT00440947
    Conditions
    Infection, Human Immunodeficiency Virus I; HIV Infection
    Interventions
    Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r); Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2010-07
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus I; HIV Infection
    InterventionAbacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r); Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
    PhasePhase 3
    Registry statusCompleted

  • ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

    NCT00335322 · start 2007-02

    Registered record
    Registry ID
    NCT00335322
    Conditions
    Human Immunodeficiency Virus (HIV)
    Interventions
    Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-02
    Completion
    2011-11
    Enrolment
    329

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV)
    InterventionTruvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
    PhasePhase 4
    Registry statusCompleted